| scholarly article | Q13442814 |
| P2093 | author name string | W Timothy Garvey | |
| P2860 | cites work | Economic costs of diabetes in the U.S. in 2012 | Q22241287 |
| Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 | ||
| Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study | Q28280445 | ||
| Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health | Q28288766 | ||
| Comparison of accuracy of diabetes risk score and components of the metabolic syndrome in assessing risk of incident type 2 diabetes in Inter99 cohort | Q28742005 | ||
| Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010 | Q29555853 | ||
| Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | Q29618673 | ||
| The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years | Q30577414 | ||
| Diet, insulin resistance, and obesity: zoning in on data for Atkins dieters living in South Beach | Q30957212 | ||
| Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria | Q31931889 | ||
| Comparative effectiveness of weight-loss interventions in clinical practice | Q33819180 | ||
| A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study | Q33888204 | ||
| XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients | Q33974818 | ||
| Bariatric surgery and long-term cardiovascular events. | Q34030064 | ||
| New options for the treatment of obesity and type 2 diabetes mellitus (narrative review) | Q34070610 | ||
| Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Soc | Q34075016 | ||
| Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects | Q34136304 | ||
| Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies | Q34170210 | ||
| Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus | Q46795016 | ||
| A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial | Q46879925 | ||
| Weight maintenance 2 years after participation in a weight loss program promoting low-energy density foods | Q47316214 | ||
| Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study | Q47321369 | ||
| Waist-hip ratio is the dominant risk factor predicting cardiovascular death in Australia | Q47366214 | ||
| Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial | Q47381748 | ||
| Comparison of continuous and intermittent anorectic therapy in obesity | Q49214454 | ||
| Biomarkers in Type 2 diabetes: improving risk stratification with the PreDx ® Diabetes Risk Score. | Q51366399 | ||
| Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. | Q51474932 | ||
| Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. | Q51922378 | ||
| Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. | Q53248709 | ||
| American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. | Q54307680 | ||
| Value of the history and physical in identifying patients at increased risk for coronary artery disease | Q70520186 | ||
| Diagnosis and classification of diabetes mellitus | Q85777959 | ||
| Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2) | Q86043312 | ||
| Performance of A1C for the classification and prediction of diabetes | Q34422138 | ||
| Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study | Q34580894 | ||
| Multicenter, placebo-controlled trial of lorcaserin for weight management | Q34660152 | ||
| Quality of life and obesity | Q34742754 | ||
| Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat | Q35006662 | ||
| Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes | Q35060170 | ||
| Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity | Q35255590 | ||
| Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial | Q35515066 | ||
| Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study | Q35677262 | ||
| Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) | Q35724113 | ||
| The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. | Q35841138 | ||
| Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide | Q36028436 | ||
| Opportunities for using lipoprotein subclass profile by nuclear magnetic resonance spectroscopy in assessing insulin resistance and diabetes prediction | Q36131593 | ||
| A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults | Q36304814 | ||
| Incident cardiovascular disease events in metabolically benign obese individuals | Q36389738 | ||
| Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes. | Q36525447 | ||
| The impact of weight loss among seniors on Medicare spending | Q36715558 | ||
| Development and validation of a patient self-assessment score for diabetes risk | Q36786384 | ||
| Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006 | Q37067113 | ||
| Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management | Q37206308 | ||
| A proposed clinical staging system for obesity | Q37384280 | ||
| The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity | Q37399447 | ||
| Medical therapy for the patient with obesity | Q37999778 | ||
| Are there still healthy obese patients? | Q38034895 | ||
| Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. | Q38067027 | ||
| Effect of a free prepared meal and incentivized weight loss program on weight loss and weight loss maintenance in obese and overweight women: a randomized controlled trial | Q38499016 | ||
| A general cardiovascular risk profile: The Framingham study | Q39774351 | ||
| Weight loss and lifetime medical expenditures: a case study with TRICARE prime beneficiaries | Q39781014 | ||
| Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. | Q40530902 | ||
| Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q42950914 | ||
| Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery | Q43234279 | ||
| AACE comprehensive diabetes management algorithm 2013. | Q43448145 | ||
| Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study | Q43580702 | ||
| The diabetes risk score: a practical tool to predict type 2 diabetes risk | Q44333486 | ||
| The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study | Q44425360 | ||
| Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia | Q44565825 | ||
| NMR-determined lipoprotein subclass profile predicts type 2 diabetes | Q46190746 | ||
| The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). | Q46434824 | ||
| P433 | issue | 5 | |
| P921 | main subject | obesity | Q12174 |
| P1104 | number of pages | 11 | |
| P304 | page(s) | 864-874 | |
| P577 | publication date | 2013-09-01 | |
| P1433 | published in | Endocrine Practice | Q15761577 |
| P1476 | title | New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach | |
| P478 | volume | 19 |
| Q34070626 | A complications-based clinical staging of obesity to guide treatment modality and intensity |
| Q26784022 | Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum |
| Q37129163 | American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease |
| Q38813584 | Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. |
| Q36515350 | Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults |
| Q27331844 | Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies |
| Q36129793 | Development of a Weighted Cardiometabolic Disease Staging (CMDS) System for the Prediction of Future Diabetes |
| Q51014289 | Improvement in chronic low back pain in an obese patient with topiramate use. |
| Q34245530 | Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance |
| Q22253010 | Long-term drug treatment for obesity: a systematic and clinical review |
| Q89851686 | Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity |
| Q51246181 | Systemic Inflammation in Severe Obese Patients Undergoing Surgery for Obesity and Weight-Related Diseases. |
| Q33750634 | The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg |
| Q37240745 | Trends in Cardiovascular Health Metrics in Obese Adults: National Health and Nutrition Examination Survey (NHANES), 1988-2014 |
| Q34503739 | Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action |
| Q35816619 | Weight maintenance: challenges, tools and strategies for primary care physicians |
Search more.